A novel autophagy enhancer as a therapeutic agent against metabolic syndrome and diabetes

Hyejin Lim, Yu Mi Lim, Kook Hwan Kim, Young Eui Jeon, Kihyoun Park, Jinyoung Kim, Hui Yun Hwang, Dong Jin Lee, Haushabhau Pagire, Ho Jeong Kwon, Jin Hee Ahn, Myung Shik Lee

Research output: Contribution to journalArticle

24 Citations (Scopus)


Autophagy is a critical regulator of cellular homeostasis, dysregulation of which is associated with diverse diseases. Here we show therapeutic effects of a novel autophagy enhancer identified by high-throughput screening of a chemical library against metabolic syndrome. An autophagy enhancer increases LC3-I to LC3-II conversion without mTOR inhibition. MSL, an autophagy enhancer, activates calcineurin, and induces dephosphorylation/nuclear translocation of transcription factor EB (TFEB), a master regulator of lysosomal biogenesis and autophagy gene expression. MSL accelerates intracellular lipid clearance, which is reversed by lalistat 2 or Tfeb knockout. Its administration improves the metabolic profile of ob/ob mice and ameliorates inflammasome activation. A chemically modified MSL with increased microsomal stability improves the glucose profile not only of ob/ob mice but also of mice with diet-induced obesity. Our data indicate that our novel autophagy enhancer could be a new drug candidate for diabetes or metabolic syndrome with lipid overload.

Original languageEnglish
Article number1438
JournalNature communications
Issue number1
Publication statusPublished - 2018 Dec 1


All Science Journal Classification (ASJC) codes

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Lim, H., Lim, Y. M., Kim, K. H., Jeon, Y. E., Park, K., Kim, J., Hwang, H. Y., Lee, D. J., Pagire, H., Kwon, H. J., Ahn, J. H., & Lee, M. S. (2018). A novel autophagy enhancer as a therapeutic agent against metabolic syndrome and diabetes. Nature communications, 9(1), [1438]. https://doi.org/10.1038/s41467-018-03939-w